Literature DB >> 3612128

Composition of gangliosides and neutral glycosphingolipids of brain in classical Tay-Sachs and Sandhoff disease: more lyso-GM2 in Sandhoff disease?

B Rosengren, J E Månsson, L Svennerholm.   

Abstract

The ganglioside composition of the brain from an individual with classical Tay-Sachs disease and from an individual with Sandhoff disease was examined using our new quantitative methods for ganglioside content determination and compared with that of age-matched control brains. The concentration of GM2 was found to be 12.2 and 13.0 mumol/g of fresh tissue in Tay-Sachs disease and in Sandhoff disease cerebral gray matter, respectively. GM2 was 86 and 87% respectively, of total gangliosides. The concentration of GM1 and, in particular, GM3 ganglioside was also found to be increased, whereas the concentration of the major di- and trisialogangliosides (GD1a, GD1b, and GT1b) had diminished markedly. There was no significant increase in level of any other ganglioside than lyso-GM2. Its concentration was 12 and 16 nmol/g in cerebral gray matter of two Tay-Sachs disease brains and 43 nmol/g in Sandhoff disease brain. The Sandhoff disease brain also differed from the classical Tay-Sachs disease brain by having a much higher concentration of gangliotriaosylceramide and globotetraosylceramide. The structures of relevant gangliosides and neutral glycolipids were established by fast atom bombardment-mass spectrometry and permethylation studies.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3612128     DOI: 10.1111/j.1471-4159.1987.tb00969.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  14 in total

Review 1.  Twenty five years of the "psychosine hypothesis": a personal perspective of its history and present status.

Authors:  K Suzuki
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

2.  Monoclonal anti-GD3 antibodies selectively inhibit the proliferation of human malignant glioma cells in vitro.

Authors:  K M Hedberg; B Dellheden; C J Wikstrand; P Fredman
Journal:  Glycoconj J       Date:  2000-10       Impact factor: 2.916

3.  Natural history of infantile G(M2) gangliosidosis.

Authors:  Annette E Bley; Ourania A Giannikopoulos; Doug Hayden; Kim Kubilus; Cynthia J Tifft; Florian S Eichler
Journal:  Pediatrics       Date:  2011-10-24       Impact factor: 7.124

4.  Sphingosylphosphorylcholine in Niemann-Pick disease brain: accumulation in type A but not in type B.

Authors:  C Rodriguez-Lafrasse; M T Vanier
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

5.  Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas.

Authors:  D C Longee; C J Wikstrand; J E Månsson; X He; G N Fuller; S H Bigner; P Fredman; L Svennerholm; D D Bigner
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 6.  [Sphingolipid storage diseases of the central nervous system: bases of biochemical and clinical heterogeneity].

Authors:  K Sandhoff; L Quintern
Journal:  Naturwissenschaften       Date:  1988-03

7.  Tay-Sachs disease with atypical chronic course and limited brain storage: alpha-locus hexosaminidase genetic compound.

Authors:  M Philippart; R E Carrel; B H Landing
Journal:  Neurochem Res       Date:  1995-11       Impact factor: 3.996

8.  Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff disease.

Authors:  Rena C Baek; Douglas R Martin; Nancy R Cox; Thomas N Seyfried
Journal:  Lipids       Date:  2008-11-26       Impact factor: 1.880

Review 9.  Lysosomal storage diseases.

Authors:  Carlos R Ferreira; William A Gahl
Journal:  Transl Sci Rare Dis       Date:  2017-05-25

Review 10.  Secondary lipid accumulation in lysosomal disease.

Authors:  Steven U Walkley; Marie T Vanier
Journal:  Biochim Biophys Acta       Date:  2008-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.